MAPRE2: A Potential Drug Target for Cancer (G10982)

Target Name: MAPRE2

NCBI ID: G10982

MAPRE2

MAPRE2: A Potential Drug Target for Cancer

MAPRE2 (Mesothelin-Asparaginyl-Proline-Ethyl Esther-2) is a protein that is expressed in various tissues throughout the body. It is a key component of the cell membrane, and its presence is required for the maintenance of tissue structure and integrity.MAPRE2 has also been shown to play a role in cancer progression, and is often used as a drug target or biomarker in cancer research.

The MAPRE2 protein is composed of four domains: an extracellular domain, a transmembrane domain, an intracellular domain, and a catalytic domain. The extracellular domain is the largest and is responsible for the protein's ability to interact with other cells and the extracellular matrix. The transmembrane domain is responsible for the protein's ability to span the cell membrane and interact with other proteins on the same membrane. The intracellular domain is responsible for the protein's ability to interact with intracellular signaling molecules, and the catalytic domain is responsible for the protein's catalytic activity.

MAPRE2 is a glycoprotein, which means that it consists of a protein that is covalently bound to a sugar molecule. This sugar molecule is typically glucose, and it allows the protein to interact with other proteins and cells.MAPRE2 is a type of glycoprotein that is expressed in many different tissues throughout the body, including the skin, the lungs, the heart, and the brain.

MAPRE2 has been shown to play a role in the development and progression of various cancers, including breast, ovarian, and colorectal cancers. It has been shown to promote the growth and survival of cancer cells, and to contribute to the development of resistance to chemotherapy.

MAPRE2 has also been shown to be a potential drug target in cancer research. By blocking the activity of MAPRE2, researchers can inhibit the growth and survival of cancer cells, and potentially lead to the development of new treatments for cancer.MAPRE2 is also being investigated as a biomarker for cancer, as its expression has been shown to be associated with the development and progression of various cancers.

In conclusion, MAPRE2 is a protein that is expressed in various tissues throughout the body and has been shown to play a role in the development and progression of cancer. As a potential drug target and biomarker, MAPRE2 is a promising target for cancer research and treatment. Further studies are needed to fully understand the role of MAPRE2 in cancer biology and to develop new treatments for this disease.

Protein Name: Microtubule Associated Protein RP/EB Family Member 2

Functions: May be involved in microtubule polymerization, and spindle function by stabilizing microtubules and anchoring them at centrosomes. May play a role in cell migration (By similarity)

The "MAPRE2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAPRE2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets